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The role of K channel activity during cell cycle pro-
gression has become a research topic of considerable
interest. Blocking of K channels inhibits the prolifera-
tion of many cell types, although the mechanism of this
inhibition is unclear. There is speculation that K chan-
nels differentially regulate the electrical potential of the
plasma membrane (Vm) during proliferation. We have
demonstrated that in tumor cells the value of Vm is
clamped to rather depolarized values by K channels
belonging to the HERG family. We report here that tu-
mor cell lines preferentially express the herg1 gene and
a truncated, N-deleted form that corresponds to herg1b.
This alternative transcript is also expressed in human
primary acute myeloid leukemias. Both HERG1 and
HERG1B proteins are expressed on the plasma mem-
brane of tumor cells and can form heterotetramers. The
expression of HERG protein isoforms is strongly cell
cycle-dependent, accounting for variations in HERG
currents along the mitotic cycle. Moreover, the blocking
of HERG channels dramatically impairs cell growth of
HERG-bearing tumor cells. These results suggest that
modulated expression of different K channels is the
molecular basis of a novel mechanism regulating neo-
plastic cell proliferation.
Potassium channels are the most diverse class of plasma
membrane ion channels, and this hetereogeneity is reflected by
the large variety of specific roles they exert in different cell
types. Besides the regulation of excitability in nerve and mus-
cle cells, and the linkage between plasma membrane and met-
abolic activity, there is now evidence that K channels are
involved in the regulation of cell proliferation (1). The cellular
mechanisms linking K channel activity and cell proliferation
remain unclear, although a possibility is that activation of K
channels might be required for the passage of cells through a
specific phase of the mitotic cycle (1, 2). K channel blockage
has been shown to be antiproliferative for numerous non-excit-
able as well as excitable cells (3–9); however, the link between
K channel activity and cell cycle progression remains elusive.
One hypothesis is that K channels might regulate cell volume,
as well as the concentration of intracellular solutes critical for
cell metabolism; alternatively, K channel activity might serve
to maintain permissive membrane potentials at critical cell
cycle checkpoints (1). Furthermore, terminally differentiated
G0 cells display a hyperpolarized value of their membrane
potential (Vm), whereas cycling and in particular tumor cells
are quite depolarized (10).
We have shown previously (11) that the depolarized state of
many tumor cell lines can be explained by the lack of classical
inward rectifier K channel-type inward rectifier K currents
accompanied by the expression of peculiar voltage-dependent
K channels, belonging to the HERG1 family (12, 13). The herg
(human eag-related) gene belongs to an evolutionarily con-
served multigenic family of voltage-activated K channels, the
eag (ether a-go`-go`) family (15). herg genes and HERG currents
(IHERG) are preferentially expressed in neoplastic cell lines of
different histogenesis, as well as in primary human endome-
trial cancers (11, 14). The functional properties of HERG chan-
nels are complex, and their contribution to the repolarization of
the cardiac action potential well understood (16). For our pur-
poses, however, it is sufficient to recall that the HERG activa-
tion and inactivation curves are such that their crossover pro-
duces maximal channel open probability between30 and50
mV in resting conditions (12, 13), thus contributing substan-
tially to the resting potential of tumor cells (12, 13). In some
neurons, the HERG role appears to be the regulation of the
action potential firing frequency (17). Recent studies (18) indi-
cate that in various normal tissues other than heart and brain,
IHERG and the erg gene are expressed only at very early stages
of embryo development and are subsequently replaced by in-
ward rectifier K channel currents.
The molecular basis of IHERG is being uncovered. HERG
channels are tetramers, with each subunit consisting of six
transmembrane domains, and both N and C termini are located
intracellularly. The HERG proteins compose the  subunit of
the channel, whereas a  subunit associating with HERG is
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represented, at least in parts of the heart, by the MIRP1
protein (19). Three different ERG proteins have been cloned in
mammals: ERG1, ERG2, and ERG3 (HERG1, HERG2, and
HERG3 in humans), with the latter being specific to the nerv-
ous tissues (20). The recently characterized genomic structure
of the herg gene encoding the HERG1 protein (herg1 gene)
consists of 15 exons, spanning about 19 kb on chromosome 7
(21, 22). Most of the exons code for the N and C termini, which
therefore appear to be putative sites for alternative splicing.
The HERG1 C terminus contains the cyclic nucleotide binding
domain (15), and an alternatively spliced product of this region
(named HERGUSO) has been identified in the heart (23), which
cannot be expressed on the plasma membrane by itself but
could modify the biophysical properties of IHERG. Conversely,
the N terminus is made up of two domains, the “eag” domain,
comprising the first 135 amino acids of the HERG1 sequence,
and the “proximal” domain, which extends from position 135 to
about position 366. The former domain, a eukaryotic PAS do-
main, is involved in the regulation of channel gating (24–26),
particularly with regard to deactivation rates, whereas the
latter is apparently involved in regulating channel activation.
An alternative transcript of the herg1 gene, displaying a short
N terminus, has been identified in mouse and human hearts,
merg1b and herg1b, respectively (27, 28). Compared with
merg1, merg1b has a different first exon (designated 1b) located
between exons 5 and 6 of the Merg1 genomic sequence. Because
the region upstream from exon 1b may contain an alternate
transcription initiation site, it is possible that merg1b repre-
sents an alternate transcript more than a splicing variant (27,
28). However, recent evidence (29) seems to exclude the expres-
sion of this transcript at the protein level in the hearts of
various species.
We thus investigated the molecular structure of herg genes
and HERG proteins in tumor cell lines. In particular, because
IHERG biophysical features (rapid deactivation kinetics and
strong dependence of the activation gate on depolarized values
of the Vm) as well as herg biomolecular characteristics (pres-
ence of multiple RNA bands ranging from 4.4 to 1.9 kDa as
revealed in Northern blot experiments) in tumor cells are quite
different from those displayed by the channel in the heart and
in herg1-transfected cells (11, 30), the expression of different
herg genes, as well as of alternate transcripts in tumor cells,
was investigated.
We report here that tumor cell lines, as well as primary
human tumors, preferentially express the herg1 gene, along
with herg1b. Both the full-length HERG1 and HERG1B pro-
teins are coexpressed and can form heterotetramers on the
plasma membrane of tumor cells. The expression of the two
HERG protein isoforms turned out to be strongly cell cycle-de-
pendent, suggesting a possible explanation for the variations in
IHERG along the mitotic cycle previously demonstrated in neu-
roblastoma cells (12). Moreover, the block of HERG channels
dramatically impaired cell growth of HERG-bearing neuroblas-
toma cells.
On the whole, these results contribute to an understanding
of the molecular basis of a novel mechanism regulating neo-
plastic cell proliferation, i.e. HERG K channels.
MATERIALS AND METHODS
Cell Culture—The human neuroblastoma SH-SY5Y and LAN1 clone
AE12 (kindly provided by Dr. G. Mugnai, University of Firenze, Italy)
cell lines, the human rhabdomyosarcoma RD12 cell line (kindly pro-
vided by Dr. P. L. Lollini, University of Bologna, Italy), and HEK 293
cells (kindly provided by Dr. S. Heinemann, University of Jena, Ger-
many) were cultured in DMEM containing 4.5 g/liter of glucose and 10%
FCS (HyClone) and incubated at 37 °C in a humidified atmosphere with
5% CO2. The human colon carcinoma H630 (kindly provided by Dr. E.
Mini, University of Firenze, Italy), the human monoblastic leukemia
FLG 29.1 (kindly provided by Dr. P. A. Bernabei, Hematology Unit,
Firenze, Italy), and the human mammary adenocarcinoma SkBr3 and
the human retinoblastoma Y-79 (kindly provided by Dr. A. Albini, IST,
Genova, Italy) cell lines were all cultured in RPMI 1640 medium con-
taining 5, 10, and 20% FCS, respectively, and incubated at 37 °C in a
humidified atmosphere with 5% CO2.
Cell Transfection—The HEK 293 cells, cultured on 100-mm Petri
dishes, were transiently transfected with herg1 cDNA cloned into Hin-
dIII/BamHI sites of the pCDNA3.1 vector (Invitrogen) by the calcium
phosphate method. Six hours before transfection the medium was re-
placed once. The precipitation solution was then added to the cell
cultures. The precipitation solution was 400 l of 2 BES-buffered
saline (50 mM BES, 280 mM NaCl, 1.5 mM Na2HPO42H2O (pH 6.96))
plus 400 l of 0.25 M CaCl2 and 36 g of the cDNA construct. The
medium was replaced 15 h later. Protein extraction, as well as control
patch clamp analysis, was performed 48–72 h post-transfection.
pCDNA3.1 without the insert was also transiently transfected as above
in the same cell line, which was used as a negative control. These cells
are referred to as MOCK.
RNase Protection Assay—The RNase Protection Assay (RPA) was
performed essentially according to Dixon and McKinnon (31). Briefly,
RNA was extracted from semiconfluent tumor cell lines (see above) by
the guanidinium/isothiocyanate method (32). Commercially available
human brain RNA (Clontech) as well as human heart RNA (Ambion)
were used as controls for herg1 and herg3 expression and for herg1b,
respectively. Thirty g of total RNA was hybridized overnight at 48 °C
with [32P]UTP-labeled RNA probes. Digestion was then performed for
1 h at room temperature with RNase A (40 g/ml) and T1 (2 g/ml).
Yeast tRNA (Invitrogen) was used as a negative control to test for the
presence of probe self-protection bands. The samples were run on a
6.6% polyacrylamide gel and exposed for 1–8 days. The human erg
probes used were the following: herg1 (nucleotides 1401–1880, Gen-
BankTM accession number NM 000238); herg2 (nucleotides 2041–2245,
GenBankTM accession number NM 030779); herg3 (nucleotides 272–
480, GenBankTM accession number AF 032897); the N-terminal herg1
clone (nucleotides 184–589, GenBankTM accession number NM 000238)
named hergN135 was produced in our laboratory (14). The probe relative
to herg1b was produced by RT-PCR (see below) from the FLG 29.1 cell
line. Human cyclophilin (Ambion) was used as an internal loading
control.
Reverse Transcription-PCR—Two g of total RNA was retrotrans-
cribed with Superscript reverse transcriptase (200 units) (Invitrogen) in
the presence of random hexamers (2.5 M). For herg1b amplification,
the cDNA thus obtained was amplified using HotStarTaq polymerase (5
units) (Qiagen) and the following primers: herg1b-up 5-CGATTC-
CAGCCGGGAAGGC-3; herg1b-down 5-TGATGTCCACGATGAG-
GTCC-3 (product size, 363 bp), according to the sequence reported in
Lees Miller et al. (28). It is worth noting that herg1b-up maps on exon
1b of the genomic sequence, whereas herg1b-down maps on exon 6 of
the same sequence that is shared by both herg1b and herg1 isoforms.
Thirty five cycles of amplification were carried out after 15 min of
enzyme activation at 95 °C as follows: 94 °C for 1 min, 56 °C for 1 min,
72 °C for 1 min. The PCR product was cloned by means of the TA
cloning system (Invitrogen) and then subcloned in pBluescript vector,
sequenced, and used for RPA experiments as reported above. PCRs
relative to human eag and Kv 1.3 transcripts were performed according
to Smith et al. (33), using the following primers: heag-up 5-CGCAT-
GAACTACCTGAAGACG-3; heag-down 5-TCTGTGGATGGGGCGAT-
GTTC-3 (product size, 479 bp); Kv 1.3-up 5-TCGAGACGCAGCTGAA-
GAC-3; Kv 1.3-down 5-GGTACTCGAAGAGCAGCCAC-3 (product
size, 350 bp).
Cloning of Herg1b from Tumor Cells—The hergb transcript was
cloned from FLG 29.1 cells with two different approaches, RT-PCR and
RACE-PCR. Briefly, poly(A) RNA was extracted by means of a poly(A)
Pure kit (Ambion), and cDNA-retrotranscribed using either oligo(dT)
primers (for RT-PCR cloning) or the 3-adapter primer according to the
3-RLM-RACE kit protocol (Ambion) (for RACE-PCR). PCR was per-
formed with Takara polymerase (2.5 units) using the following primers:
UP primer, 5-AGGGAGCCAAGTCCTCCATGG-3 (which maps into
the sequence relative to the human exon 1b (dbEST Id: 8445856));
DOWN primer, 5-GCGGCCGCACTGCCCGGGTCCGAG-3 (which
maps at the end of the herg1 sequence with the addition of a NotI
restriction site). The amplified band of 2.5 kb was purified and cloned
into the pCR2.1 vector (Invitrogen) using the TA cloning kit (Invitro-
gen). 3-RACE PCR was performed according to the protocol provided in
the Ambion kit, using 2.5 units of HotStarTaq polymerase (Qiagen), and
using the same UP primer as reported above for first round. The second
round of amplification was performed using herg1b-specific primers: UP
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primer 5-CAGGCAAAGCTTAGGGAGCCAAGTCCTCCATGG-3
(which corresponds to the above reported up primer used for RT-PCR
plus a HindIII restriction site); DOWN primer 5-CAGCGCGCGGCC-
GCCTGGGTGAGCCACGTGTC-3 (which maps in the untranslated
region of the herg1 sequence (see above) and contains a NotI restriction
site). In this case the amplified band was cloned into HindIII/NotI sites
of pBluescript (Stratagene) vector. All the cloned bands were sent off for
sequencing by PRIMM DNA Sequencing Service.
Protein Chemistry—For Western blot experiments both total cell
lysate and membrane proteins were used as described previously (34).
For membrane decoration two anti-HERG antibodies were used: an
anti-ERG antibody raised against the C terminus (residues 1121–1137
of rat ERG1, Alomone Labs) and an anti-HERG antibody against the N
terminus (residues 1–135 of human ERG1) developed in our laboratory
(14). The latter serum was immunopurified on a column preadsorbed
with the antigen and tested by means of enzyme-linked immunosorbent
assay. N-Glycosidase F (Roche Molecular Biochemicals) was used fol-
lowing the manufacturer’s instructions. For proteinase K (Roche Mo-
lecular Biochemicals) treatment, confluent cell cultures, seeded on
100-mm Petri dishes or on 25-cm2 flasks, were washed with PBS and
incubated with 3 ml of a solution containing 10 mM HEPES, 150 mM
NaCl, and 2 mM CaCl2 (pH 7.4) with or without 200 g/ml proteinase K,
at 37 °C for 30 min; enzyme activity was then stopped with 2 ml of
ice-cold PBS containing 6 mM phenylmethylsulfonyl fluoride, 25 mM
EDTA. After three washes in ice-cold PBS, membrane proteins were
isolated and processed as above. For immunoprecipitation 3 mg of total
protein lysate was cleared by incubation with protein A-Sepharose (50
l of a 50% slurry) for 2 h at 4 °C. Anti-HERG antibody against the N
terminus was added, and the samples were incubated on ice for 1 h. 40
l of protein A-Sepharose was then added, and each sample was incu-
bated overnight at 4 °C. The immunoprecipitates were washed in lysis
buffer and ice-cold PBS prior to SDS-PAGE. Membranes were then
immunoblotted with anti-ERG C terminus antibody. Super Signal
(Pierce) was used for blot visualization.
Cell Synchronization and Cell Cycle Analysis—SH-SY5Y neuroblas-
toma cells were synchronized by hydroxyurea treatment according to
Arcangeli et al. (12). Retinoic acid treatment was performed according
to Arcangeli et al. (35). The distribution in the cell cycle phases was
determined by flow cytometry; samples of cell suspension (106 cells/ml)
were stained with propidium iodide (PI) as described by Vindeløv and
Christensen (36). The samples were then analyzed using a FACScan
flow cytometer (BD Biosciences) equipped with a 5-watt argon ion laser.
The fluorescence of PI-stained nuclei was excited at 488 nm, and his-
tograms of the number of cells versus linear integrated red fluorescence
were recorded for 50,000 nuclei/sample. DNA histograms were analyzed
using the MultiCycle DNA content and cell cycle analysis software
(Phoenix Flow Systems, San Diego).
Cell Proliferation Assay—The human neuroblastoma cell lines SH-
SY5Y and LAN1, cultured as above, were seeded in 96-well plates
(Corning Glass) at a cell density of 1.8 104 and 1.2 104 cells per well,
respectively, and then starved for 16 h in DMEM containing 1% FCS.
After this time, DMEM containing 2.5% FCS, with or without HERG
channel blocker (E4031 200 or 50 M, and WAY 123,398, 50 M, final
concentrations), was added, and this was considered to be the time 0 of
the experiment. At different times of incubation, cells were assayed
using the colorimetric Cell Proliferation Reagent WST-1 (Roche Molec-
ular Biochemicals), whose tetrazolium salt is cleaved by mitochondrial
enzymes so that the amount of dye developed (read at 450 nm, reference
at 630 nm) directly correlates to the number of metabolically active cells
in the culture. Absorbance of culture medium plus wst-1 in the absence
of cells was the blank position for the enzyme-linked immunosorbent
assay reader (ELx-800, Biotek Instruments).
Data Acquisition and Analysis—RPA and Western blot images were
acquired by an HP4C scanner, and the relative bands were analyzed by
Scion Image software.
RESULTS
Experiments performed were aimed at determining the mo-
lecular basis of HERG currents in tumor cells. The first point to
be explored was whether cancer cells expressed different herg
genes, namely herg1, herg2, or herg3. For this purpose, RPA
experiments were performed using appropriately cloned herg1,
-2, and -3 probes on tumor cell lines of different histogenesis:
human neuroblastoma (SH-SY5Y), human rhabdomyosarcoma
(RD12), human colon carcinoma (H630), human mammary car-
cinoma (SkBr3), and human monoblastic leukemia (FLG 29.1).
The results of these experiments are shown in Fig. 1. As shown
in Fig. 1A, all of the tumor cell lines tested express the herg1
gene, although at different intensities (see also the densitomet-
ric analysis reported in Fig. 3a). In particular, both SH-SY5Y
and FLG 29.1 cells appear to overexpress the herg1 gene, as
suggested previously (11). On the other hand, no human tumor
cell line expresses the herg2 gene (Fig. 1B), except for the
human retinoblastoma cell line Y-79. This expression, which
represents the positive control in our experiments, is in keep-
ing with the well known expression of erg2 gene in the retina,
at least in rat (20). As for herg3 expression (Fig. 1C), only
SkBr3 cells express the gene at good levels, as compared with
human brain. Therefore, these cells express both herg3 and
herg1, with the latter expressed at relatively low intensity.
Because Kv channel encoding genes other than herg, like eag
or Kv 1.3, have reportedly been linked to cell proliferation in
different models (37, 38), we tested whether the above-men-
tioned genes were overexpressed in the tumor cell lines under
FIG. 1. herg-1, -2, and -3 expression in various human tumor
cell lines. RNA extracted from SH-SY5Y human neuroblastoma cells,
RD12 human rhabdomyosarcoma cells, H630 human colon carcinoma
cells, SKBr3 human mammary carcinoma cells, and FLG 29.1 human
monoblastic leukemia cells was probed with the herg1, -2, and -3 probes
as described under “Materials and Methods.” Human brain RNA was
used as a control for herg1 and herg3, whereas RNA from human
retinoblastoma Y-79 cells was used as a control for herg2 expression.
Human cyclophilin (hcyc) (Ambion) was used as an internal control and
yeast tRNA as a negative control to test for probe self-protection bands.
A, herg1 (1-day exposure); B, herg2 (5-day exposure); C, herg3 (1-day
exposure). The protected bands corresponding to the above-mentioned
genes are indicated by an arrow.
HERG1 Isoforms in Tumor Cells 2949
 at UNIV DEG
LI STUDI DI FIREN, on Novem
ber 13, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
study. Fig. 2 shows the expression of eag and Kv 1.3 genes in
SH-SY5Y, FLG 29.1, H630, RD12, and SkBr3 cells, as detected
by RT-PCR. It is evident that, despite the good quality of all the
cDNAs tested (see gapdh expression in the lower panel of Fig.
2), only SH-SY5Y, as reported previously (39), and RD12 cells,
as expected (40), express the eag gene. Kv 1.3 is not expressed
in any of the tumor cell lines examined, although it is present
in human peripheral resting lymphocytes as reported previ-
ously (33).
On the whole, data presented in Figs. 1 and 2 demonstrate
that cancer cell lines preferentially express the herg1 gene.
Neither herg2 nor -3 nor the other Kv encoding genes that have
been proposed to play a role in the control of cell proliferation
(i.e. eag and Kv 1.3) are expressed at the RNA level, irrespec-
tive of the histological origin of the cancer cell lines tested. This
result rules out the possibility that the herg RNA profile (11) as
well as the HERG biophysical features specific of the different
tumor cell lines that we have tested are due to coexpression of
different proportions of the products of the three herg genes.
The possibility of deletions as well as alternative splicing prod-
ucts of the herg1 gene in tumor cells was then investigated.
Because tumor IHERG was demonstrated previously (30) to
display fast deactivation kinetics, a feature associated with a
deletion in the N-terminal domain, we first looked for the
existence of herg1 deletions and/or splicing modifications at
this level.
A probe was constructed (N(135) herg1 terminus) for RPA
experiments, comprising the first 135 amino acids of the
HERG1 sequence, i.e. the eag domain. The results of this ex-
periment are reported in Fig. 3. The eag domain is present in
the herg1 transcript of all the tumor cell lines tested; however,
when comparing the densitometric analysis of the results ob-
tained with the herg1 probe, encompassing a conserved region
of the gene (Fig. 1), with the densitometric analysis of the
experiments performed with the N(135) herg1 terminus probe
(see Fig. 3, a and b), it is evident that the eag domain is
expressed at a lower level, especially in SH-SY5Y and FLG 29.1
cells. A possible explanation of these data is that tumor cells
express both a full-length herg1 mRNA, and a truncated form
of the latter, lacking part or the entire N terminus.
The possibility that such N-truncated RNA could belong to
the already identified herg1 alternative transcript named
herg1b was then tested. First, the expression of herg1b was
studied in two different tumor cell lines (SH-SY5Y and FLG
29.1 cells) by RT-PCR. As shown in Fig. 4A, herg1b mRNA is
indeed expressed in both the cell lines tested. The possibility of
the simultaneous expression of herg1 and herg1b in tumor cell
lines was then investigated by constructing probes for RPA
experiments comprising first the entire herg1b exon and part of
exon 6, which is shared by herg1 and herg1b genes (27, 28). If
both herg1 and herg1b are expressed in tumor cells, two RPA
bands would be expected with molecular weights 258 and 363
bp, respectively. This result indeed occurred (see Fig. 4B) both
in SH-SY5Y and FLG 29.1 cells and in the heart. Note that this
is not common to all tissues expressing herg1, as only a lower
RPA band was detectable in brain RNA, corresponding to the
herg1 gene. Moreover, observing the two bands present in FLG
29.1 cells, it is evident that the upper band (attributable to
herg1b) has a higher intensity compared with the lower band
corresponding to herg1. As tumor cell lines are deregulated in
terms of their RNA expression, we analyzed whether herg1b
mRNA could be detected in primary human tumors. We dem-
onstrated recently (41) that the herg1 gene is expressed in
human myeloid leukemias; hence, we chose these cells as sam-
ples because they are not contaminated by other cell types,
such as stromal or smooth muscle cells, that could express the
herg1b transcript (27, 28). As shown in Fig. 4C, all of the
FIG. 2. Expression of eag and Kv 1.3 transcripts in tumor cell
lines. RNA was extracted from SH-SY5Y, RD12, H630, FLG 29.1, and
SKBr3 tumor cell lines, as well as from normal peripheral blood lym-
phocytes (PBL). cDNA was retrotranscribed and amplified using spe-
cific primers for the eag and Kv 1.3 K channel genes as reported under
“Materials and Methods.” For each cell line used, lane 1 represents
amplification of the Kv 1.3 gene, and lane 2 represents amplification of
the eag gene. Lymphocyte cDNA was amplified for the Kv 1.3 gene and
was used as the positive control. Lower panel, RT-PCR of the control
gene gapdh in the various tumor cell lines as above.
FIG. 3. Expression of the herg1 N-terminal domain in tumor
cell lines. The RNA samples were probed with the herg1 probe encom-
passing the first 135 amino acids of the N-terminal domain (herg1N135)
as described under “Materials and Methods.” Human cyclophilin (hcyc)
(Ambion) was used as an internal control and yeast tRNA as a negative
control to test for the presence of the probe self-protection bands.
Exposure was 1 day. herg1- and hcyc-protected bands are indicated by
an arrow. a, densitometric analysis of the herg1 expression, relative to
Fig. 1A; b, densitometric analysis of the herg1N135 expression reported
in this figure. Signals of the herg1 and herg1N135 protected bands were
normalized using the corresponding values of cyclophilin.
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primary myeloid leukemias we tested expressed the herg1b
exon, ruling out the possibility that such expression is exclu-
sively an artifact related to the altered gene expression occur-
ring in established tumor cell lines.
The nature of the transcript containing the herg1b exon in
tumor cells was then investigated by cloning the entire tran-
script from tumor cells. Clones obtained by RT-PCR and 3-
RACE PCR (see “Materials and Methods”) were sequenced
demonstrating that tumors cells do express the entire herg1b
alternative transcript (GenBankTM accession number
AJ512214). The herg1b transcript cloned from tumor cells was
identical to that identified in human heart (27, 28), except for
two polymorphisms (in position 689 and 953 of the submitted
sequence), and identical to that reported for the herg1 sequence
cloned from neuroblastoma cells (11). It is worth noting here
that, as stated in the Introduction and reported under “Mate-
rials and Methods,” the sequence of the herg1b exon was con-
firmed on the genomic sequence of chromosome 7, suggesting
the possibility that herg1b represents an alternate transcript
more than a splice variant.
Furthermore, because data gathered from our RPA experi-
ments showed that, in FLG 29.1 cells, herg1b represented the
greatest amount of the total HERG mRNA, the next step was to
determine whether the encoded protein HERG1B was ex-
pressed on the plasma membrane. Western blot experiments
were, therefore, performed on SH-SY5Y neuroblastoma and
FLG 29.1 leukemia cells, using anti-HERG antibodies, specific
for both the C and N termini (see “Materials and Methods”).
When experiments were performed with an anti-C terminus
antibody (Fig. 5A), two main bands were detectable in herg1-
transfected cells, weighing 135 and about 155 kDa, respec-
tively, as expected (29, 42). On the other hand, in SH-SY5Y and
FLG 29.1 cells, two main groups of bands could be seen: an
upper group ranging from 135 to 155 kDa, and a lower group
ranging from 85 to 100 kDa. It is worth noting that the upper
group of bands is more evident in SH-SY5Y cells, whereas they
are barely detectable in FLG 29.1 cells. The possibility that
both the two groups represented HERG proteins expressed on
the plasma membrane was then tested by performing experi-
ments on cells treated with specific enzymes used to evaluate
the glycosylation state (N-glycosidase F) as well as the plasma
membrane expression (proteinase K) of HERG proteins. As
shown in Fig. 5B, when membrane extracts from both SH-
SY5Y and FLG 29.1 cells were treated with N-glycosidase F
(lanes 1), both the bands of 155 and those 100 kDa shifted
to lower molecular weights. Furthermore, when cells were
treated with proteinase K (Fig. 5B, lanes 3) both the bands of
155 and those of 100 kDa disappeared, and only the bands
of135 and85 kDa could be seen. The results were similar in
both cell lines tested; the only difference was that all the bands
of lower molecular weight were preferentially expressed in
FLG 29.1 cells, whereas those of higher molecular weight were
observed only after longer exposure of the autoradiographic
film (see Fig. 5B, inset).
The results of these experiments suggest that both SH-SY5Y
and FLG 29.1 cells express two HERG isoforms on their plasma
membranes: one corresponding to the full-length protein (135
kDa), and its various glycosylated forms (the bands of 155
kDa); and the second corresponding to HERG1B, which has a
molecular mass of 85 kDa in the unglycosylated, immature
form, and various glycosylated forms expressed on the plasma
membrane (the bands of 100 kDa). To verify this, experi-
ments were performed using the antibody directed against the
HERG N-terminal domain (see “Materials and Methods”). As
shown in Fig. 5C, the reactivity of this antibody on HERG-
transfected HEK 293 cells is comparable with that of the anti-
C-terminal antibody (compare C with A), whereas in SH-SY5Y
cells only the bands of higher molecular mass, ranging from
135 to 155 kDa, can be detected with this antibody. Similar
results were obtained in FLG 29.1 cells with very long exposure
(not shown).
On the whole, it appears plausible to conclude that tumor cell
lines express two mature, highly glycosylated HERG proteins
on their plasma membrane, a full-length HERG1 and the
HERG1B isoform. In order to explore the possibility that these
two proteins could form heterotetramers in cancer cells, as
observed in transfected oocytes (27, 28), immunoprecipitation
experiments were performed. Proteins from both herg1-trans-
fected HEK 293 cells and SH-SY5Y cells were immunoprecipi-
tated using the anti-N-terminal antibody that recognizes only
the herg1 product, and the subsequent Western blot was dec-
orated with the anti-C-terminal antibody that is capable of
recognizing both isoforms. As shown in Fig. 6, the immunopre-
cipitated proteins contain only HERG1 full-length in the trans-
FIG. 4. herg1b expression in tumor cell lines. A, RT-PCR. RNA
extracted from FLG 29.1 and SH-SY5Y (see upper labels) was retro-
transcribed and amplified using primers specific for herg1b (see “Ma-
terials and Methods”). The lane labeled noRNA-noDNA represents the
negative control. The two bands indicated by the arrow were sequenced
and showed a 93% identity with the mouse erg1b (GenBankTM accession
number AF034762). B, RPA experiments. RNA extracted from brain,
heart, SH-SY5Y, and FLG 29.1 cell lines was hybridized with the
herg1b probe cloned from FLG 29.1 (see “Materials and Methods”). St,
32P-UTP-labeled molecular weight marker (Ambion). The results were
obtained after 8 days of exposure and show a specific herg1b-protected
band in all the samples tested except for the brain. Human cyclophilin
(Ambion) was used as an internal control and yeast tRNA as a negative
control to test for the presence of the probe self-protection bands. C,
RT-PCR on primary acute myeloid leukemias. RNA was extracted from
various primary acute myeloid leukemias of different FAB phenotypes
(M0 to M7, see upper labels) and processed as described in the legend to
A. RNA from FLG 29.1 human monoblastic cell line was used as positive
control. Lane labeled as noRNA-noDNA represents the negative
control.
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fected HEK 293 cells (lane 2), whereas bands indicating the
presence of both HERG1 and HERG1B proteins are detected in
SH-SY5Y cells (lane 4).
It is, therefore, likely that tumor cell lines not only express
both HERG1 and HERG1B proteins on their plasma mem-
brane but that these proteins can form heterotetramers in
these cells. Such heterotetramers can be composed of different
amounts of each single protein, as suggested by the different
appearance of Western blots on SH-SY5Y cells and FLG 29.1
cells.
We have demonstrated previously (12) that biophysical fea-
tures, such as the activation voltage, of the HERG currents in
neuroblastoma cells are cell cycle-dependent. The possibility
now exists that such features can be accounted for by differen-
tial expression of HERG1B and full-length HERG1 proteins.
Therefore, SH-SY5Y cells were synchronized by treatment with
hydroxyurea (HU) and retinoic acid (RA), as reported previ-
ously (12). After a 15-h treatment with HU, neuroblastoma
cells were blocked at the G1/S boundary. Then, after HU with-
drawal, cells enter almost synchronously into S phase, so that
after 6 h a high percentage of cells is in the middle of the S
phase and reaches the S/G2 boundary after 8 h (Fig. 7A).
Western blot experiments performed on the same cell prepara-
tion (Fig. 7B) showed that expression of the HERG1B mature
form is significantly up-regulated in the middle of S phase as
compared with unsynchronized cells, and to G1/S HU-blocked
cells (see also the densitometric analysis of the two HERG
isoforms reported in inset b). Conversely, when SH-SY5Y cells
were treated for 11 days with RA, a strong synchronization of
the cells in G1 was achieved (Fig. 8A) (12). Under these condi-
tions, a strong up-regulation of HERG proteins can be detected
in Western blot experiments (Fig. 8B) in agreement with re-
sults reported previously (35). This up-regulation apparently
involves both of the isoforms, although a stronger increase in
the intensity of the mature full-length HERG1 band can be
observed (see the densitometric analysis reported in inset b).
On the whole, results presented in Figs. 7 and 8 are consist-
ent with the previously reported modulation of IHERG activa-
tion curves during the cell cycle (12); in fact, prevalence of
HERG1B expression shifts the activation voltage toward depo-
larized values (see the mouse erg1b encoded currents reported
in Refs. 27 and 28), whereas the IHERG of the full-length HERG
has an activation voltage that is more hyperpolarized.
These results allow us to ask a fundamental question: what
is the putative role of IHERG in the regulation of cancer cell
proliferation? A preliminary answer to this question was ob-
FIG. 5. HERG protein expression in herg1-transfected cells and in tumor cell lines. Membrane proteins were extracted, separated by
SDS-PAGE, and immunoblotted with the anti-HERG C-terminal antibody (Alomone Labs) as reported under “Materials and Methods.” A, HERG
protein expression in HEK 293 MOCK-transfected cells (293 MOCK), in HEK 293 transfected with the herg1 clone (293 HERG1), in SH-SY5Y cells,
and in FLG 29.1 cells. The molecular weight of a protein standard (Bio-Rad) is reported on the left. Twenty g of proteins were loaded in the case
of HEK 293-transfected cells and 50 g in the case of SH-SY5Y and FLG 29.1 cells. B, HERG protein expression in SH-SY5Y cells (left panel) and
FLG 29.1 cells (right panel) treated with various enzymes as described under “Materials and Methods.” Lanes 1, membrane extracts treated with
N-glycosidase F; lanes 2, untreated control extracts; lanes 3, cells treated with proteinase K. The inset over the right panel relative to FLG 29.1
cells represents a longer exposure of the autoradiographic film corresponding to the full-length HERG protein bands (see “Results”). C, HERG
protein expression in HEK 293 MOCK-transfected cells, in HEK 293 transfected with the herg1 clone (293 HERG1), and in SH-SY5Y cells using
an N-terminal antibody (see “Materials and Methods”). The molecular weight of a protein standard (Bio-Rad) is reported on the left.
FIG. 6. Immunoprecipitation of HERG proteins in herg1-trans-
fected HEK 293 cells and SH-SY5Y cells. Three mg of total cell
extracts from herg1-transfected HEK 293 as well as SH-SY5Y (lanes 2
and 4, respectively) were immunoprecipitated using anti-HERG N ter-
minus. The membrane was further decorated with anti-HERG C ter-
minus. Twenty g of HEK 293 proteins and 40 g of SH-SY5Y proteins
were also loaded (lanes 1 and 3, respectively). The molecular weight of
a protein standard (Bio-Rad) is reported on the left.
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tained by testing the effects of a specific IHERG inhibitor
(E4031) on proliferation of neuroblastoma cells, by utilizing the
same approach used previously (41) in acute myeloid cells. The
results of these experiments are reported in Fig. 9; it is evident
that E4031 significantly impairs proliferation in SH-SY5Y cells
(left panel), whereas it does not significantly affect cell growth
in the LAN1 clone AE12 cells (right panel), which do not ex-
press IHERG.
2 Similar results were obtained with another
HERG blocker, namely Way 123,398 (see insets in Fig. 9), in a
different set of experiments. IHERG clearly affects proliferation
of the SH-SY5Y cells; however, because the currents of both
HERG1 and HERG1B proteins are blocked by these com-
pounds, no conclusion about the differential role of the two
HERG isoforms in cell growth can be inferred.
DISCUSSION
Results reported in this paper clearly show that various
tumor cell lines preferentially express the herg1 gene along2 G. Hofmann, personal communication.
FIG. 7. Cell cycle-dependent expression of full-length versus truncated HERG protein in SH-SY5Y cells. SH-SY5Y cells were
synchronized by HU treatment as reported under “Materials and Methods.” At various times, cells were processed for both cytofluorimetric
analysis and membrane extraction. Membrane extracts were then separated by SDS-PAGE and blotted; membranes were then decorated with the
anti-HERG C-terminal antibody as reported above. Three separate experiments were performed, and a typical experiment is reported. A,
cytofluorimetric analysis. a, control, unsynchronized cells (percentage of cells in G1  54.4, S  34.1, and G2  11.5); b, cells treated with HU for
15 h (percentage of cells in G1  80.5, S  17.1, and G2  2.4); c, cells after 3 h of HU withdrawal (percentage of cells in G1  40.3, S  57.1, and
G2  2.6); d, cells after 6 h of HU withdrawal (percentage of cells in G1  39.8, S  56.2, and G2  3.9); e, cells after 8 h of withdrawal of HU
(percentage of cells in G1  29.7, S  56.1, and G2  14.2). B, Western blot of HERG proteins extracted from SH-SY5Y cells treated with HU as
reported in A. HERG1m, HERG1 protein mature bands; HERG1i, HERG1 protein immature band; HERG1Bm, HERG1B protein mature bands;
HERG1Bi, HERG1B protein immature band. Inset b, densitometric analysis of the bands corresponding to the mature form of HERG1 (white bars)
as well as of HERG1B (black bars) isoform.
FIG. 8. Expression of full-length ver-
sus truncated HERG protein in RA-
treated SH-SY5Y. SH-SY5Y cells were
treated with RA for 11 days as reported
under “Materials and Methods.” The re-
sults are typical of four similar experi-
ments. A, cytofluorimetric analysis. a,
control, untreated cells (percentage of
cells in G1  45.9, S  39.9, and G2 
14.2); b, RA-treated cells (percentage of
cells in G1  92.6, S  5.3, and G2  2.1).
B, Western blot of HERG proteins ex-
tracted from SH-SY5Y cells treated with
RA as reported in A. Labels on the right
are the same as in Fig. 7. Inset b, densi-
tometric analysis of the expression of the
mature forms of HERG1 (white bars) as
well as of HERG1B (black bars) isoforms.
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with a truncated form of the HERG1 protein that corresponds
to the alternative transcript of herg1 first discovered in the
heart, herg1b. The herg1b isoform is also expressed in primary
human tumors. Moreover, the data reported here show that the
corresponding proteins, HERG1 and HERG1B, are differen-
tially expressed during cell cycle phases and that HERG cur-
rents are capable of modulating cell proliferation in tumor
cells.
The expression of herg1, -2, and -3 was studied in various
human tumor cell lines in order to define better the molecular
basis of HERG currents discovered in tumor cells. It was dem-
onstrated previously (11, 30) that IHERG biophysical properties
(rapid deactivation kinetics and strong dependence of the acti-
vation gate on depolarized Vm values) as well as biomolecular
features (presence of multiple RNA bands revealed by North-
ern blot) in tumor cells are quite different from those displayed
in the heart and in herg1-transfected cells. As reported here, all
the tumor cell lines tested expressed the herg1 gene, whereas
herg2 expression is limited to human retinoblastoma cells and
herg3 to a human mammary carcinoma cell line. Whereas the
expression of herg2 in retinoblastoma cells is in keeping with
the well documented expression of erg2 in the retina of the rat
(20) and quail (43), the presence of herg3 in a cell line of
epithelial origin is quite surprising, because erg3 was first
characterized as a nervous system-specific gene (20).
The following question thus arises: does the herg gene(s)
expression in tumor cells represent 1) the re-expression of an
embryonic gene or 2) the ectopic expression of a gene that is
turned off in fully differentiated cell types? This is an impor-
tant point for cancer researchers, as it has been well docu-
mented that neoplastic cells display biochemical and behav-
ioral features of both embryonic, highly immature cells and
novel, often metaplastic characteristics, completely altering
the phenotype of the transformed cell. In neuroblastoma and
rhabdomyosarcoma cells, herg1 expression appears to be the
re-expression of an embryonic gene (see our results on quail
embryos (43)). The type of expression for tumors of epithelial
origins is less clear as neither herg1 nor herg3 genes are ex-
pressed in epithelial tissues in adults (20) or embryos (43).
The data reported here also demonstrate that tumor cell
lines and primary human tumors express an alternative tran-
script of herg1, which results in an N-terminal truncated form.
It is worth noting that in human tumors many cancer-associ-
ated genes are alternatively spliced (44). Although the function
of most of these variants is not well defined, some of them have
antagonistic activities related to cell death mechanisms. In
many types of cancer and cancer cell lines, the ratios of the
splice variants are frequently shifted toward the anti-apoptotic
splice isoforms. In this regard, the herg1 gene may be among
such genes that are alternatively spliced in neoplastic cells,
raising interesting questions as to the different roles exerted by
the full-length versus the spliced isoform in tumor cell estab-
lishment and maintenance.
These results also indicate that the truncated herg1 is the
alternative transcript herg1b. The whole transcript of herg1b
was cloned by RT-PCR and 3-RACE in FLG 29.1 leukemia
cells. This is the first report of the entire transcript in humans
obtained thus far (GenBankTM accession number AJ512214).
During the 3-RACE cloning procedure, we also cloned another
herg variant that resulted in the fusion of the herg1b exon with
the hergUSO sequence. This transcript, lacking the 104 amino
acid C-terminal domain necessary for channel recapitulation,
is not expressed at the protein level on the plasma membrane
and thus does not contribute to IHERG currents,
3 but its puta-
tive role in tumor cells is now under investigation.
In contrast, the HERG1B protein is expressed on the plasma
membrane and does form heterotetramers with the herg1 gene
product in tumor cells, as demonstrated clearly by immunopre-
cipitation experiments reported in this paper. The herg1b tran-
script was first identified in heart (27, 28), but the correspond-
ing protein is not expressed in adult hearts (29). Although it
was suggested (29) that the protein could be expressed during
development, the exact role of HERG1B in cell physiology is
still unknown. Therefore, the demonstration that this channel
protein is expressed in tumors, while confirming that tumor
cells often express embryonic and/or alternatively spliced
genes, opens new and interesting perspectives on the role of
herg1 isoforms in tissues other than heart.
The expression of herg1b in neoplastic cells could explain
both the peculiar pattern of mRNA expression and the biophys-
ical features of HERG currents observed in tumor cells (11, 12,
30). HERG currents in such cells, especially in leukemia cell
lines, display fast deactivation kinetics that may be attributa-
ble to expression of an N-terminal truncated HERG in these
cells (30). As described previously (27, 28), the current encoded
by herg1b displays most of the above biophysical features when
expressed in oocytes.
Further experiments performed on synchronized cells show
that whereas the truncated HERG1B form is up-regulated
during the S phase, the full-length HERG1 protein increases
its expression on the plasma membrane during the G1 phase.
These results give a molecular dimension to the previously
demonstrated variations of HERG activation curves, as well as
of Vm during cell cycle progression of neuroblastoma cells (12).
This result is also in keeping with other reports demonstrating
cell cycle modulation of K channel expression (1), and in
general with the reported link between K channels and cell
cycle progression (45, 46). In different models (1) it has been
reported that an increase in K channel expression and activ-
ity occurs at the G1/S boundary and that such an increase is
necessary for cells to traverse the cell cycle. In HERG-bearing
tumor cells, such as SH-SY5Y, an increase in the HERG1B/
HERG1 ratio on the plasma membrane occurs as cells proceed
3 A. Arcangeli, A. Beechetti, L. Guasti, and O. Crociani, unpublished
data.
FIG. 9. Effect of IHERG block on cell proliferation of SY5Y and
LAN1 (clone AE12) cells. Cells were serum-starved overnight with
1% FCS and then cultured in 2.5% FCS in the absence (a) or in the
presence of the HERG inhibitor E4031 (50 M (b) and 200 M (c), final
concentrations), as reported under “Materials and Methods.” Cell pro-
liferation was assessed by means of the cell proliferation reagent WST1
assay after 48 h of incubation. Insets, comparative effect of 50 M E4031
(gray bars), 50 M Way 123,398 (white bars) as compared with the
controls (black bars) on cell proliferation of SH-SY5Y (left inset) and
LAN1 (clone AE12) (right inset) after 72 h of incubation. Values are
expressed as optical density. Each experimental point represents the
mean  S.E. of four determinations carried out in two separate exper-
iments. Student’s t test for paired samples was carried out. *, signifi-
cantly different at the p  0.05 level as compared with the control.
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through the S phase. This increase could account for the depo-
larization of Vm occurring during S phase progression of neu-
roblastoma cells, as reported previously (12), and the necessity
of HERG channel activity for proliferation. This is demon-
strated by impaired neuroblastoma and leukemia (41) cell pro-
liferation in the presence of HERG-specific inhibitors. In other
words, a tightly clamped Vm value is required for each cell cycle
phase and can be obtained by alternatively switching the
above-mentioned ratio; the Vm oscillations are apparently nec-
essary for neuroblastoma cell cycling, so that cell proliferation
stops either when the full-length HERG1 isoform is turned on
and Vm hyperpolarizes (see RA-treated cells) or when the
HERG isoforms-based clock is impaired by totally blocking
HERG currents.
Finally, the truncated HERG1B isoform lacks the PAS do-
main, an oxygen-sensing domain of basic helix-loop-helix pro-
teins, like HIF-1. The latter is a transcriptional activator that
is up-regulated by hypoxia and is responsible for gene activa-
tion under hypoxic conditions (47). It is worth noting here that
hypoxia is a main determinant of tumor progression and is
currently regarded as a major hindrance to cancer therapy (48,
49). The ability of tumor cells to express two types of HERG
proteins, one endowed with and the other lacking the PAS
domain, could be an advantage for cancer growth and progres-
sion. In hypoxia, cells could thus sense the decreased oxygen
tension by PAS, lowering the HERG1B/HERG1 ratio, thus
leading to a shifting of the activation curve of HERG currents
and to hyperpolarize Vm, limiting K
 loss (50). This could
permit the cell to survive in G1 without entering into the
apoptotic pathway, because K efflux is recognized as one of
the earliest events in cells undergoing apoptosis (51). When
the oxygen supply is restored and/or growth factors are pro-
duced, HERG-bearing tumors could undergo a remodeling of
their HERG channels on the plasma membrane, increasing the
HERG1B/HERG1 ratio, thus clamping Vm to depolarized val-
ues compatible with sustained cell growth.
Data presented in this paper, and in particular the demon-
stration of protein expression of the herg1b transcript, provide
a novel perspective for a therapeutic approach to control
HERG-expressing human primary tumors like endometrial
cancers (14), acute myeloid leukemias (41), astrocytomas,4 and
colo-rectal cancers.5 Various strategies (specific drugs or spe-
cific antisense oligonucleotides) could be designed to block spe-
cifically the altered HERG currents in tumors without affecting
the Ikr currents found in cardiac myocytes or other non-trans-
formed cell types.
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